Horizon Pharma PLC (HZNP) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $0.34 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.31. The company posted revenue of $204.69 million in the period, compared to analysts expectations of $197.27 million. The company’s revenue was up 80.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 EPS.
Many Wall Street Analysts have commented on Horizon Pharma PLC. Shares were Reiterated by Mizuho on May 3, 2016 to “Buy” and Lowered the Price Target to $ 25 from a previous price target of $34 .
Horizon Pharma PLC closed down -1.18 points or -8.09% at $13.41 with 92,10,760 shares getting traded on Friday. Post opening the session at $13.95, the shares hit an intraday low of $13.0501 and an intraday high of $14.163 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Dec 10, 2015, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 4,456 shares at $20.00 per share price. According to the SEC, on Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price. On Mar 17, 2015, Jeff Himawan (director) sold 554,564 shares at $22.47 per share price, according to the Form-4 filing with the securities and exchange commission.
Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.